Jefferies Downgrades Hims & Hers Health to Hold, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Glen Santangelo downgraded Hims & Hers Health (HIMS) from Buy to Hold and reduced the price target from $17 to $15, indicating a more cautious outlook on the company's stock.

April 16, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jefferies downgraded Hims & Hers Health from Buy to Hold and lowered the price target from $17 to $15, suggesting a tempered expectation for the stock's performance.
The downgrade by Jefferies from Buy to Hold reflects a more conservative stance on Hims & Hers Health's future stock performance. The reduction in the price target from $17 to $15 further underscores the analyst's tempered expectations for the company's financial growth or stock price appreciation in the short term. Such analyst actions often lead to a negative perception among investors, potentially causing a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100